Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

References

• JordanK, SippelC, SchmollHJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143–1150. doi:10.1634/theoncologist.12-9-114317914084
   PubMed Web of Science ®Google Scholar
• RoilaEBF. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 2003;1(1):46. doi:10.1186/1477-7525-1-4614521717
   PubMedGoogle Scholar
• AaproM. CINV: still troubling patients after all these years. Support Care Cancer. 2018;26(Suppl 1):5–9. doi:10.1007/s00520-018-4131-329556808
   PubMed Web of Science ®Google Scholar
• GuoL, PengH, CaiHL, et al. Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. Cancer Chemother Pharmacol. 2019;83(4):727–734. doi:10.1007/s00280-019-03777-730680523
   PubMed Web of Science ®Google Scholar
• HsiehRK, ChanA, KimHK, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015;23(1):263–272. doi:10.1007/s00520-014-2373-225120009
   PubMed Web of Science ®Google Scholar
• NavariRM. Management of chemotherapy-induced nausea and vomiting. Drugs. 2016;73:249–262.
   Web of Science ®Google Scholar
• HilariusDL, KloegPH, Van der WallE, GundyCM, AaronsonNK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107–117. doi:10.1007/s00520-010-1073-921258948
   PubMed Web of Science ®Google Scholar
• MolassiotisA, AaproM, DicatoM, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47(5):839–848.e834. doi:10.1016/j.jpainsymman.2013.06.01224075401
   PubMed Web of Science ®Google Scholar
• JordanK, GrallaR, JahnF, MolassiotisA. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202. doi:10.1016/j.ejphar.2013.09.07324157984
   PubMed Web of Science ®Google Scholar
• IiharaH, FujiiH, YoshimiC, et al. Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol. 2016;21(2):409–418. doi:10.1007/s10147-015-0908-226475354
   PubMed Web of Science ®Google Scholar
• RapoportB, SmitT. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2017;16(6):697. doi:10.1080/14740338.2017.132586828460548
   PubMed Web of Science ®Google Scholar
• AaproM, CaridesA, RapoportBL, SchmollHJ, ZhangL, WarrD. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20(4):450–458. doi:10.1634/theoncologist.2014-022925795636
   PubMed Web of Science ®Google Scholar
• MilnesV, GonzalezA, AmosV. Aprepitant: a new modality for the prevention of postoperative nausea and vomiting: an evidence-based review. J PeriAnesth Nurs. 2015;30(5):406–417. doi:10.1016/j.jopan.2014.11.01326408515
   PubMed Web of Science ®Google Scholar
• CamposD, PereiraJR, ReinhardtRR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19(6):1759–1767. doi:10.1200/JCO.2001.19.6.175911251007
   PubMed Web of Science ®Google Scholar
• SimonVB, LichinitserMR, NavariRM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer Chemother Pharmacol. 2002;94(11):3032–3041.
   Google Scholar
• AaproM, MolassiotisA, DicatoM, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986–1992. doi:10.1093/annonc/mds02122396444
   PubMed Web of Science ®Google Scholar
• MajumdarAK, HowardL, GoldbergMR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291–300. doi:10.1177/009127000528346716490805
   PubMed Web of Science ®Google Scholar
• BubaloJS, CheralaG, McCuneJS, MunarMY, TseS, MaziarzR. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol. 2012;52(4):586–594. doi:10.1177/009127001139824321415280
   PubMed Web of Science ®Google Scholar
• SalmanFT, DiCristinaC, ChainA, AfzalAS. Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. J Pediatr Surg. 2018;54:1384–1390.30381138
   PubMed Web of Science ®Google Scholar
• YeoW, MoFKF, SuenJJS, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2008;113(3):529–535. doi:10.1007/s10549-008-9957-918327706
   PubMed Web of Science ®Google Scholar
• HuZ, ChengY, ZhangH, et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled Phase III trial. Support Care Cancer. 2014;22(4):979–987. doi:10.1007/s00520-013-2043-924276953
   PubMed Web of Science ®Google Scholar
• ZhangL, LuS, FengJ, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452–458. doi:10.1093/annonc/mdx69829092012
   PubMed Web of Science ®Google Scholar
• ChenLK, ChengY, ZhangHY, et al. Efficacy of aprepitant in preventing high-dose cisplatin-induced nausea and vomiting in Chinese patients with lung cancer. Chin J New Drugs Clin Remedies. 2015;32(10):757–763. doi:10.14109/j.cnki.xyylc.2015.10.006
   Google Scholar
• NakadeS, OhnoT, KitagawaJ, et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2008;63(1):75–83. doi:10.1007/s00280-008-0713-y18317761
   PubMed Web of Science ®Google Scholar
• MassaroAM, LenzKL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39(1):77–85. doi:10.1345/aph.1E24215562136
   PubMed Web of Science ®Google Scholar
• SanchezRI, WangRD, BakhtiarR, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metabo Dispos. 2004;32(11):1287–1292. doi:10.1124/dmd.104.000216
   PubMed Web of Science ®Google Scholar